Mirtazapine added to
antipsychotics appears to improve the clinical picture of
schizophrenia, including both negative and positive symptoms. This study explored the effect of adjunctive
mirtazapine on neurocognition in patients with
schizophrenia who had shown an insufficient response to first-generation
antipsychotics (FGAs). Thirty-seven
schizophrenia patients, who were at least moderately ill despite their FGA treatment, received add-on
mirtazapine (n=19) or placebo (n=18) in a 6-wk double-blind, randomized trial. Widely used neuropsychological tests were performed to explore visual-spatial functions, verbal and visual memory, executive functions, verbal fluency and general mental and psychomotor speed. The data were analysed on the modified intent-to-treat basis with last observation carried forward. False discovery rate was applied to correct for multiple testing.
Mirtazapine outperformed placebo in the domains of visual-spatial ability and general mental speed/attentional control as assessed by, correspondingly, Block Design and Stroop dots. The difference in the degree of change (i.e. change while on
mirtazapine minus that on placebo) was 18.6% (p=0.044) and 11.1% (p=0.044), respectively. Adjunctive
mirtazapine might offer a safe, effective and cost-saving option as a neurocognitive enhancer for FGA-treated
schizophrenia patients. Mirtazapine+FGA combinations may become especially useful in light of the currently increasing attention towards FGAs. Larger and longer studies that incorporate functional outcomes, as well as comparisons with second-generation
antipsychotics are, however, still needed for more definite conclusions.